PathogenDx Appoints Foremost Industry and Topic Experts as Its Advanced Microarray Testing Platform Sets New Standards in DNA-Based TestingContinue reading
Author Archive: Koerber-Walker, Joan
Humabiologics partners with Shanghai Besto Biotechnology to distribute human biomaterials in China
Humabiologics’ products are now available to researchers in China for use in regenerative medicine translational research, cell therapy, bioprinting, tissue & disease modeling, and drug screening applications.Continue reading
TGen partners with Deepcell to advance detection, analysis and treatment of disease
Technology platform provides state-of-the-art imaging and analysis of individual cellsContinue reading
UArizona Researchers Develop AI-driven Method for Diagnosing Lung Disease
Feb. 17, 2022 – Metabolite technology developed in the College of Medicine – Tucson has been licensed to startup MetFora.Continue reading
Treatment for autism symptoms earns ASU researchers patent
February 2, 2022 – A new treatment for autism, created by Arizona State University researchers and their colleagues, has been granted a patent by the U.S. Patent Office. Continue reading
Mayo Clinic Center for Regenerative Medicine
February 3, 2022 / Susan Buckles – Envisioning the future of regenerative medicine elicits images of an operating room that also is a manufacturing facility. Patients undergoing surgery could have immediate access to products biomanufactured within the operating room or even within their own bodies.
Understudied lncRNAs Could Help Enable Early Detection Of Potentially Deadly Liver Disease
TGen-Temple comprehensive review highlights recently discovered associations between long noncoding RNAs and specific diseasesContinue reading
PathogenDx Announces the CE Marking of Its Next-Generation COVID-19 Testing Technology for the Simultaneous Detection of SARS-CoV-2 (COVID-19) and Its Variants
The Technology Provides Medical Laboratories with a Rapid (6 hours), Affordable and Accurate Test for the Detection of SARS-CoV-2 (“COVID-19”) and its Variants (“VOC”) and (“VOI”) without Sequencing.
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models
TUCSON, AZ / ACCESSWIRE / February 1, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute diseases; has published a study in Scientific Reports (Tadeo Bermudez lead author) highlighting the effectiveness of the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb)in reducing Acute Respiratory Distress Syndrome (ARDS)/Ventilator Induced Lung Injury (VILI) symptoms in both rat and porcine animal models.
Continue reading